Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jessa Hospital
With
Hasselt University
Primary objective Evaluate the efficacy of a novel emollient for the management of ARD in comparison with the current standard of care in breast cancer patients
Secondary Objective 1 Compare the ARD-related symptoms of in breast cancer patients treated with the novel emollient and the standard institutional skin care.
Secondary Objective 2 Compare the dermatologic quality of life of in breast cancer patients treated with the novel emollient and the standard institutional skin care.
Secondary Objective 3 Correlate the severity of ARD with the applied RT parameters and personal - medical characteristics
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of breast cancer and underwent lumpectomy or mastectomy
Scheduled for radiotherapy: hypofractionation regimen (16 or 16+5 boost fractions) at the Jessa Hospital (Hasselt, BE)
Age ≥ 18 years
Able to comply to the study protocol
Able to sign written informed consent
Signed written informed consent
You may not be if
Previous irradiation to the breast region
Metastatic disease
Patients with pre-existing skin rash, ulceration or open wound in the treatment area
Substance abuse patients or patients with medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results as judged by the investigator •- Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator
Clareo Health | Novel Skin Care Product for the Management of Acute Radiodermatitis
